CDK4 and neoplasm: Given that CDK4/6is can increase the expression of PD-L1 in tumor cells, a large number of studies have investigated the anti-tumor and immune regulatory effects of CDK4/6i sin combination with anti-PD-1/PD-L1 antibodies.